- Home
- ADNT vs IRON Comparison
ADNT vs IRON Comparison
Compare ADNT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADNT
- IRON
- Stock Information
- Founded
- ADNT 2016
- IRON 2017
- Country
- ADNT Ireland
- IRON United States
- Employees
- ADNT N/A
- IRON N/A
- Industry
- ADNT Auto Parts:O.E.M.
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ADNT Consumer Discretionary
- IRON Health Care
- Exchange
- ADNT Nasdaq
- IRON Nasdaq
- Market Cap
- ADNT 1.9B
- IRON 2.1B
- IPO Year
- ADNT N/A
- IRON N/A
- Fundamental
- Price
- ADNT $22.80
- IRON $89.66
- Analyst Decision
- ADNT Hold
- IRON Strong Buy
- Analyst Count
- ADNT 9
- IRON 13
- Target Price
- ADNT $22.50
- IRON $102.23
- AVG Volume (30 Days)
- ADNT 866.9K
- IRON 454.8K
- Earning Date
- ADNT 11-05-2025
- IRON 11-11-2025
- Dividend Yield
- ADNT N/A
- IRON N/A
- EPS Growth
- ADNT N/A
- IRON N/A
- EPS
- ADNT N/A
- IRON N/A
- Revenue
- ADNT $14,409,000,000.00
- IRON N/A
- Revenue This Year
- ADNT $0.02
- IRON N/A
- Revenue Next Year
- ADNT N/A
- IRON N/A
- P/E Ratio
- ADNT N/A
- IRON N/A
- Revenue Growth
- ADNT N/A
- IRON N/A
- 52 Week Low
- ADNT $10.04
- IRON $30.82
- 52 Week High
- ADNT $26.16
- IRON $95.95
- Technical
- Relative Strength Index (RSI)
- ADNT 40.88
- IRON 83.00
- Support Level
- ADNT $22.01
- IRON $68.82
- Resistance Level
- ADNT $23.74
- IRON $78.17
- Average True Range (ATR)
- ADNT 0.88
- IRON 3.40
- MACD
- ADNT -0.21
- IRON 1.56
- Stochastic Oscillator
- ADNT 18.80
- IRON 79.27
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion and fiscal 2025 is guided to about $14.4 billion as foreign exchange helps offset some divested business.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.